A solid Q4 on the back of a solid CMD

CMD: Strong profit guidance, weaker on distribution

Heads-up ahead of CMD (Dec 10th)

Novo Nordisk AS: 1 director

A director at Novo Nordisk AS bought 6,450 shares at 312.500DKK and the significance rating of the trade was 78/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

Nordic non-life insurance - Q3 reporting wrap

Insurance ensures growth

Q3: +15% adj. PTP beat from Savings/Insurance

Wind at its back

Nordic non-life insurance - Q2 reporting wrap

Strong insurance outcome and financials

Stronger insurance and profit sharing

Heads-up for Q2-report, 11 July

AUM rebound drives earnings growth

Norway: Best ideas Q2'25

Insurance trip: 16 insurers in three days

Non-life have price increases > inflation in all markets, most in Norway. Life insurance growth with rapid growth & dividend payments. Prefer ALMB, Sampo, Solid, Tryg among non-life; STB for life

ROE held back by too-high capital base

Zealand Pharma (Buy, TP: DKK950.00) - Dapiglutide likely next catalyst

Q1 revenue missed expectations on lower reimbursement revenue, while operating profit was a beat, as opex was below our forecast and consensus. The 2025 guidance was maintained for opex of DKK2,000m–2,500m. We believe the next potential share-price catalyst is the top-line results from the phase Ib dapiglutide trial in Q2e. We reiterate our BUY, but have cut our target price to DKK950 (1,000).

Storebrand (Buy, TP: NOK149.00) - Insurance repricing on track

Q1 PTP before amortisation was NOK1,167m, up 8% YOY, driven by strong growth in Banking and Insurance. While high sales activity had a negative impact on the insurance cost ratio, the combined ratio continued to improve through premium growth of 20% YOY, leaving Storebrand close to the 90–92% target for 2025. We have made fairly limited EPS revisions for 2026–2027e, and reiterate our BUY and NOK149 target price.

Novo Nordisk (Buy, TP: DKK900.00) - Accelerated Wegovy roll-out ahead

Q1 LCY figures beat our forecasts, while the 2025 guidance was cut to 13–21% LCY sales growth YOY and 16–24% LCY operating profit growth YOY due to weaker GLP-1 sales. We have lowered our rebate for US Ozempic but maintain our 52% Wegovy rebate (in line with the Q1 rebate when adjusting for de-stocking). We reiterate our BUY and DKK900 target price.

Softer operating profit, better financials

Adj PTP +5%/-2%, on better financials, but much weaker op.profit. Softer fee, insurance and opex behind the miss, financials beat. Cons.est.rev -2-4%, stock -2% to 4% on the operating profit miss